Science 37 Agrees to SPAC Merger With LifeSci Acquisition II

Science 37 Inc., a digital operating system that facilitates clinical trials, has agreed to go public through a reverse merger with a blank-check company.

The Los Angeles-based firm will merge with special purpose acquisition company LifeSci Acquisition II Corp., according to an announcement Friday, which confirmed a Bloomberg News report. The deal values Science 37 at $1.05 billion, including debt.

The transaction will include a $200 million private placement from investors including BlackRock Inc., Lux Capital, Mubadala Investment Co., PPD Inc. and the SPAC sponsor’s affiliate, LifeSci Venture Partners, the statement showed.

Science 37, whose name ...